ASPIRA-aXA
Pseudophakic reliability for you and your patients
The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the new cut-out haptic design. This posterior-chamber IOL an be conveniently implanted using small-incision technology while adhering to surgical routine.
Overview of topics
MonofocalASPIRA-aXA
Personal
Contact
| Type | Monofocal 1-piece posterior chamber lens, foldable |
| Optic diameter | 7.0 mm |
| Total diameter | 11.0 mm |
| Material | Glistening-free, hydrophilic acrylic, UV blocker |
| Optic features | Aspherical anterior surface, aberration-free, 360° LEC barrier, HD optic |
| Haptic design | Cut-out haptics |
| Constants for IOL calculation | Please click here |
| XL diopter range | Preloaded SAFELOADER® 10.0 to 30.0 D in 0.5 D steps Compact Line |
Preloaded implantation system
SIMPLE. INTUITIVE. FAST.
SAFELOADER®
More about the ASPIRA-aXA
ASPIRA-aXA – versatile potential applications
ASPIRA-aXA provides a custom solution for the most diverse needs. Possible applications range from standard cataract surgery to refractive surgery and combined interventions in retinal surgery.
XL optic: pseudophakic reliability
Panoramic IOL
Due to its XL 7.0 mm optic, this posterior chamber lens supplies the best conditions for long-term pseudophakic reliability for the patient. The extended fundus view, which is enabled by the possibility of a rhexis diameter of up to 6.5 mm, represents an enormous contribution to preventive patient management and early detection of ocular diseases.
Risk factors such as diabetes mellitus or hypertension are continuously increasing in our population.
Especially for this group within the cataract patients, the ASPIRA-aXA lays the foundations for long-term pseudophakic reliability.
APPROX. 20% – DIABETES TYPE 2
In the age group of the average cataract patient
OVER 60% – HYPERTENSION
Of over-65s
From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.
ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.
Intraoperative image (using Verion) with implanted ASPIRA-aXA*. (1) Edge of the XL optic. (2) Rhexis, diameter 6.0 mm.
Intraoperative fundus image**. (1) Edge of the XL optic.
* Courtesy of Professor G. Duncker, Halle.
** Courtesy of Professor M. Bolz, Linz, Austria.
XL optic: pseudophakic reliability
Large pupils
The ASPIRA-aXA is also an ideal treatment option for patients with large pupils. In these patients, the mesopic pupil width often exceeds the diameter of the IOL optic. Off-axis rays are scattered on the edge of the optic or pass the IOL and strike the retina as stray light. The result can be an increased incidence of dysphotopsia. With a conventional 6.0 mm optic, the patient could be affected by edge effects or other light phenomena.
APPROX. 20%
SCOTOPIC PUPIL DIAMETER ≥6 mm
APPROX. 10%
MESOPIC PUPIL DIAMETER ≥6 mm
The ASPIRA-aXA with its XL optic is an ideal treatment option for large pupils.
IOL with 6.0 mm optic
IOL with 7.0 mm optic
Simulated beam guidance, based on a simulation using OpticStudio 16.5 Zemax with a 6 mm optic and a 7 mm optic; pupil size – both 6 mm.
Cut-out haptics
Stable positioning
Scheimpflug image*
ASPIRA-aXA is positioned securely within the capsular bag, Ø pupil: 4.74 mm / Ø XL optic: 7.0 mm
* Courtesy of Professor M. Bolz, Linz, Austria.
7.0 mm optic – preloaded
SAFELOADER®
SIMPLE. INTUITIVE. FAST.
Separate components for maximum safety
The contactless preloaded implantation system offers a maximum of safety due to separation of the components. Both the IOL and the injector undergo separate sterilization processes. The isolated storage of the IOL ensures that it only comes into contact with the coating additives of the cartridge immediately prior to the surgery.
Easy to use: maximum flexibility
Another strength of the SAFELOADER® lies in its intuitive, easy handling. The ASPIRA-aXA can be conveniently implanted using small-incision technology while adhering to surgical routine.
Recommended injector: Medicel AccujectTM injector 2.0
Recommended application: in-the-bag
Extended product line
Compact Line
Premium IOL ASPIRA-aXA
Your advantages of the premium IOL platform
Clinical performance
What do the experts say?
Dr. J. Schrecker, Glauchau
“Implantation can be performed with the same incision width as with a standard IOL.”
Personal Statement, 2019
Dr. E. Becker/ M. Bonsemeyer, Oranienburg
“The ASPIRA-aXA with its enlarged XL optic represents a promising approach to minimize dysphotopsia.”
Piskula, M. Becker, E. (2018). Reduzierte pseudophake Dysphotopsien durch vergrößerte IOL-Optik. Presentation DGII 2018.
Prof. W. Sekundo, Marburg
“The large ASPIRA-aXA optic has proven itself in phaco-vitrectomies because it allows an edge-free view into the outer retinal periphery.”
Personal Statement, 2018
Prof. G. Duncker, Halle
“The patient response has been overwhelmingly positive.”
Personal Statement, 2018
Takamura, MD, PhD
“The creation of a larger capsulorhexis with implantation of a 7.0 mm optic IOL contributed to a larger anterior capsule opening after cataract surgery in patients with DM [diabetes mellitus].”
Takamura, Y., et al. Large capsulorhexis with implantation of a 7,0 mm optic lens during cataract surgery in patients with diabetes mellitus. J Catract Refract Surg 2014; 40(11):1850-1856.
Outstanding material meets best-in-class technology
A material to win you over
High transmission. High quality.
High Abbe number. High contrast sensitivity.*
A high Abbe number, as a quality measure of the imaging properties of IOLs, is associated with
*Zhao, H., Mainster, M. (2007). The effect of chromatic dispersion on pseudophakic optical performance. Br J Ophthalmol. 91 (9):1225-1229.
Clinical results*
An IOL to win you over
The ASPIRA-aXA has proven its excellent clinical properties.
Best visual results
0% Negative dysphotopsia
100% Patient satisfaction
Excellent contrast sensitivity
* HumanOptics AG (2018). Interim Study Analysis, Data on file.
** Hohberger, B., et al. (2007). Measuring contrast sensitivity in normal subjects with OPTEC 6500: influence of age and glare. Graefes Arch Clin Exp Ophthalmol, 245, 1805-1814.
Application
Publications
Reports from clinical application
Borkenstein A. F., Borkenstein E. M.
Creating Hybrid Monovision with 7.0 mm XL Optic and High-Add AMD Intraocular Lenses (XL-MAGS) in a Patient with Retinitis Pigmentosa
Case Rep Ophthalmol 2019;10:304-311; doi: 10.1159/000503093
Click here for full report
ASPIRA-aXA
Media reports
This post is also available in: German
OUR
CUSTOMER SERVICE
YOUR
QUESTIONS
Our experts support you with your questions at any time.
Successful ESCRS in Paris
News
For numerous interested visitors and exhibitors, the 37th ESCRS Congress in Paris ended on the 18th of September 2019. HumanOptics AG can also look back on a successful exhibition. The focus of this year’s booth was set on the ASPIRA-aXA posterior chamber lens with XL optic and the unique CUSTOMFLEX® ARTIFICIALIRIS iris implant. The brisk […]